首页 > 最新文献

JAMA Psychiatry最新文献

英文 中文
Polygenic Risk Scores and Twin Concordance for Schizophrenia and Bipolar Disorder. 精神分裂症和躁郁症的多基因风险评分和双生子一致性。
IF 22.5 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-12-01 DOI: 10.1001/jamapsychiatry.2024.2406
Jie Song, Joëlle A Pasman, Viktoria Johansson, Ralf Kuja-Halkola, Arvid Harder, Robert Karlsson, Yi Lu, Kaarina Kowalec, Nancy L Pedersen, Tyrone D Cannon, Christina M Hultman, Patrick F Sullivan

Importance: Schizophrenia and bipolar disorder are highly heritable psychiatric disorders with strong genetic and phenotypic overlap. Twin and molecular methods can be leveraged to predict the shared genetic liability to these disorders.

Objective: To investigate whether twin concordance for psychosis depends on the level of polygenic risk score (PRS) for psychosis and zygosity and compare PRS from cases and controls from several large samples and estimate the twin heritability of psychosis.

Design, setting, and participants: In this case-control study, psychosis PRS were generated from a genome-wide association study (GWAS) combining schizophrenia and bipolar disorder into a single psychosis phenotype and compared between cases and controls from the Schizophrenia and Bipolar Twin Study in Sweden (STAR) project. Further tests were conducted to ascertain if twin concordance for psychosis depended on the mean PRS for psychosis. Structural equation modeling was used to estimate heritability. This study constituted an analysis of existing clinical and population datasets with genotype and/or twin data. Included were twins from the STAR cohort and from the Swedish Twin Registry. Data were collected during the 2006 to 2013 period and analyzed from March 2023 to June 2024.

Exposures: PRS for psychosis based on the most recent GWAS of combined schizophrenia/bipolar disorder.

Main outcomes and measures: Psychosis case status was assessed by clinical interviews and/or Swedish National Register data.

Results: The final cohort comprised 87 pairs of twins with 1 or both affected and 59 unaffected pairs from the STAR project (for a total of 292 twins) as well as 443 pairs with 1 or both affected and 20 913 unaffected pairs from the Swedish Twin Registry. Among the 292 twins (mean [SD] birth year, 1960 [10.8] years; 158 female [54.1%]; 134 male [45.9%]), 134 were monozygotic twins, and 158 were dyzygotic twins. PRS for psychosis was higher in cases than in controls and associated with twin concordance for psychosis (1-SD increase in PRS, odds ratio [OR], 2.12; 95% CI, 1.23-3.87 on case status in monozygotic twins and OR, 2.74; 95% CI, 1.56-5.30 in dizygotic twins). The association between PRS for psychosis and concordance was not modified by zygosity. The twin heritability was estimated at 0.73 (95% CI, 0.30-1.00), which overlapped with the estimate in the full Swedish Twin Registry (0.69; 95% CI, 0.43-0.85).

Conclusions and relevance: In this case-control study, using the natural experiment of twins, results suggest that twins with greater inherited liability for psychosis were more likely to have an affected co-twin. Results from twin and molecular designs largely aligned. Even as illness vulnerability is not solely genetic, PRS carried predictive power for psychosis even in a modest sample size.

重要性:精神分裂症和躁狂症是高度遗传性的精神疾病,具有很强的遗传和表型重叠性。可以利用孪生子和分子方法来预测这些疾病的共同遗传责任:研究精神病的双生子一致性是否取决于精神病的多基因风险评分(PRS)水平和子代性,并比较几个大样本中病例和对照的PRS,估计精神病的双生子遗传率:在这项病例对照研究中,精神病PRS是从一项全基因组关联研究(GWAS)中产生的,该研究将精神分裂症和躁狂症合并为一个单一的精神病表型,并对瑞典精神分裂症和躁狂症双胞胎研究(STAR)项目中的病例和对照进行了比较。我们还进行了进一步的测试,以确定孪生子在精神病方面的一致性是否取决于精神病的平均PRS。结构方程模型用于估计遗传率。本研究对现有临床和人口数据集的基因型和/或双胞胎数据进行了分析。研究对象包括来自 STAR 队列和瑞典双胞胎登记处的双胞胎。数据收集时间为2006年至2013年,分析时间为2023年3月至2024年6月:主要结果和测量指标:通过临床访谈和/或瑞典国家登记数据评估精神病病例状态:最终队列包括来自 STAR 项目的 87 对受影响或同时受影响的双胞胎和 59 对未受影响的双胞胎(共 292 对双胞胎),以及来自瑞典双胞胎登记处的 443 对受影响或同时受影响的双胞胎和 20 913 对未受影响的双胞胎。在这 292 对双胞胎中(平均 [SD] 出生年份为 1960 [10.8] 岁;女性 158 [54.1%];男性 134 [45.9%]),134 对为单卵双胞胎,158 对为双卵双胞胎。病例的精神病PRS高于对照组,并且与双胞胎的精神病一致性相关(PRS增加1-SD,单卵双胞胎病例的几率比[OR]为2.12;95% CI为1.23-3.87;双卵双胞胎的几率比[OR]为2.74;95% CI为1.56-5.30)。精神病 PRS 与一致性之间的关系并不因同卵双生而改变。双胞胎的遗传率估计为 0.73(95% CI,0.30-1.00),与瑞典双胞胎登记处的估计值(0.69;95% CI,0.43-0.85)相吻合:在这项利用双胞胎自然实验进行的病例对照研究中,结果表明,遗传性精神病发病率较高的双胞胎更有可能有一个受影响的同卵双胞胎。双胞胎和分子设计的结果基本一致。即使疾病的易感性并不完全是遗传因素,但即使样本量不大,PRS 也具有预测精神病的能力。
{"title":"Polygenic Risk Scores and Twin Concordance for Schizophrenia and Bipolar Disorder.","authors":"Jie Song, Joëlle A Pasman, Viktoria Johansson, Ralf Kuja-Halkola, Arvid Harder, Robert Karlsson, Yi Lu, Kaarina Kowalec, Nancy L Pedersen, Tyrone D Cannon, Christina M Hultman, Patrick F Sullivan","doi":"10.1001/jamapsychiatry.2024.2406","DOIUrl":"10.1001/jamapsychiatry.2024.2406","url":null,"abstract":"<p><strong>Importance: </strong>Schizophrenia and bipolar disorder are highly heritable psychiatric disorders with strong genetic and phenotypic overlap. Twin and molecular methods can be leveraged to predict the shared genetic liability to these disorders.</p><p><strong>Objective: </strong>To investigate whether twin concordance for psychosis depends on the level of polygenic risk score (PRS) for psychosis and zygosity and compare PRS from cases and controls from several large samples and estimate the twin heritability of psychosis.</p><p><strong>Design, setting, and participants: </strong>In this case-control study, psychosis PRS were generated from a genome-wide association study (GWAS) combining schizophrenia and bipolar disorder into a single psychosis phenotype and compared between cases and controls from the Schizophrenia and Bipolar Twin Study in Sweden (STAR) project. Further tests were conducted to ascertain if twin concordance for psychosis depended on the mean PRS for psychosis. Structural equation modeling was used to estimate heritability. This study constituted an analysis of existing clinical and population datasets with genotype and/or twin data. Included were twins from the STAR cohort and from the Swedish Twin Registry. Data were collected during the 2006 to 2013 period and analyzed from March 2023 to June 2024.</p><p><strong>Exposures: </strong>PRS for psychosis based on the most recent GWAS of combined schizophrenia/bipolar disorder.</p><p><strong>Main outcomes and measures: </strong>Psychosis case status was assessed by clinical interviews and/or Swedish National Register data.</p><p><strong>Results: </strong>The final cohort comprised 87 pairs of twins with 1 or both affected and 59 unaffected pairs from the STAR project (for a total of 292 twins) as well as 443 pairs with 1 or both affected and 20 913 unaffected pairs from the Swedish Twin Registry. Among the 292 twins (mean [SD] birth year, 1960 [10.8] years; 158 female [54.1%]; 134 male [45.9%]), 134 were monozygotic twins, and 158 were dyzygotic twins. PRS for psychosis was higher in cases than in controls and associated with twin concordance for psychosis (1-SD increase in PRS, odds ratio [OR], 2.12; 95% CI, 1.23-3.87 on case status in monozygotic twins and OR, 2.74; 95% CI, 1.56-5.30 in dizygotic twins). The association between PRS for psychosis and concordance was not modified by zygosity. The twin heritability was estimated at 0.73 (95% CI, 0.30-1.00), which overlapped with the estimate in the full Swedish Twin Registry (0.69; 95% CI, 0.43-0.85).</p><p><strong>Conclusions and relevance: </strong>In this case-control study, using the natural experiment of twins, results suggest that twins with greater inherited liability for psychosis were more likely to have an affected co-twin. Results from twin and molecular designs largely aligned. Even as illness vulnerability is not solely genetic, PRS carried predictive power for psychosis even in a modest sample size.</p>","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"1246-1252"},"PeriodicalIF":22.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11359115/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142080333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Suicide Risk-A Specific Intervention Target. 自杀风险--特定干预目标。
IF 22.5 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-12-01 DOI: 10.1001/jamapsychiatry.2024.2273
Kelly L Green, Shari Jager-Hyman, Maria A Oquendo
{"title":"Suicide Risk-A Specific Intervention Target.","authors":"Kelly L Green, Shari Jager-Hyman, Maria A Oquendo","doi":"10.1001/jamapsychiatry.2024.2273","DOIUrl":"10.1001/jamapsychiatry.2024.2273","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"1171-1172"},"PeriodicalIF":22.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142287726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Psychiatric Symptoms, Cognition, and Symptom Severity in Children. 儿童的精神症状、认知能力和症状严重程度。
IF 22.5 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-12-01 DOI: 10.1001/jamapsychiatry.2024.2399
Adam Pines, Leonardo Tozzi, Claire Bertrand, Arielle S Keller, Xue Zhang, Susan Whitfield-Gabrieli, Trevor Hastie, Bart Larsen, John Leikauf, Leanne M Williams

Importance: Mental illnesses are a leading cause of disability globally, and functional disability is often in part caused by cognitive impairments across psychiatric disorders. However, studies have consistently reported seemingly opposite findings regarding the association between cognition and psychiatric symptoms.

Objective: To determine if the association between general cognition and mental health symptoms diverges at different symptom severities in children.

Design, setting, and participants: A total of 5175 children with complete data at 2 time points assessed 2 years apart (aged 9 to 11 years at the first assessment) from the ongoing Adolescent Brain and Cognitive Development (ABCD) study were evaluated for a general cognition factor and mental health symptoms from September 2016 to August 2020 at 21 sites across the US. Polynomial and generalized additive models afforded derivation of continuous associations between cognition and psychiatric symptoms across different ranges of symptom severity. Data were analyzed from December 2022 to April 2024.

Main outcomes and measures: Aggregate cognitive test scores (general cognition) were primarily evaluated in relation to total and subscale-specific symptoms reported from the Child Behavioral Checklist.

Results: The sample included 5175 children (2713 male [52.4%] and 2462 female [47.6%]; mean [SD] age, 10.9 [1.18] years). Previously reported mixed findings regarding the association between general cognition and symptoms may consist of several underlying, opposed associations that depend on the class and severity of symptoms. Linear models recovered differing associations between general cognition and mental health symptoms, depending on the range of symptom severities queried. Nonlinear models confirm that internalizing symptoms were significantly positively associated with cognition at low symptom burdens higher cognition = more symptoms) and significantly negatively associated with cognition at high symptom burdens.

Conclusions and relevance: The association between mental health symptoms and general cognition in this study was nonlinear. Internalizing symptoms were both positively and negatively associated with general cognition at a significant level, depending on the range of symptom severities queried in the analysis sample. These results appear to reconcile mixed findings in prior studies, which implicitly assume that symptom severity tracks linearly with cognitive ability across the entire spectrum of mental health. As the association between cognition and symptoms may be opposite in low vs high symptom severity samples, these results reveal the necessity of clinical enrichment in studies of cognitive impairment.

重要性精神疾病是导致全球残疾的主要原因之一,而功能性残疾的部分原因往往是各种精神疾病的认知障碍。然而,关于认知与精神症状之间的关联,研究报告却始终得出看似相反的结论:目的:确定在不同症状严重程度的儿童中,一般认知与精神健康症状之间的关联是否存在差异:从 2016 年 9 月到 2020 年 8 月,美国 21 个研究机构对正在进行的青少年大脑和认知发展(ABCD)研究中的 5175 名儿童进行了一般认知因子和精神健康症状评估,这些儿童在两个时间点的评估数据完整,且相隔两年(首次评估时年龄为 9 到 11 岁)。多项式模型和广义加法模型可推导出不同症状严重程度的认知与精神症状之间的连续关系。数据分析时间为2022年12月至2024年4月:主要评估认知测试总分(一般认知)与儿童行为检查表报告的总症状和特定症状之间的关系:样本包括 5175 名儿童(2713 名男性 [52.4%] 和 2462 名女性 [47.6%];平均 [SD] 年龄为 10.9 [1.18] 岁)。之前报道的关于一般认知与症状之间关系的混合研究结果可能由几种潜在的、相互对立的关系组成,这些关系取决于症状的类别和严重程度。线性模型发现,一般认知与心理健康症状之间存在不同的关联,这取决于所询问的症状严重程度的范围。非线性模型证实,在症状负担较低时,内化症状与认知能力呈显著正相关,而在症状负担较高时,内化症状与认知能力呈显著负相关:本研究中心理健康症状与一般认知之间的关系是非线性的。内化症状与一般认知之间既有显著的正相关,也有显著的负相关,具体取决于分析样本中被询问的症状严重程度范围。这些结果似乎调和了之前研究中参差不齐的发现,之前的研究隐含地假定症状严重程度与整个心理健康范围内的认知能力呈线性关系。由于在症状严重程度低与症状严重程度高的样本中,认知能力与症状之间的关联可能是相反的,这些结果揭示了在认知障碍研究中临床丰富化的必要性。
{"title":"Psychiatric Symptoms, Cognition, and Symptom Severity in Children.","authors":"Adam Pines, Leonardo Tozzi, Claire Bertrand, Arielle S Keller, Xue Zhang, Susan Whitfield-Gabrieli, Trevor Hastie, Bart Larsen, John Leikauf, Leanne M Williams","doi":"10.1001/jamapsychiatry.2024.2399","DOIUrl":"10.1001/jamapsychiatry.2024.2399","url":null,"abstract":"<p><strong>Importance: </strong>Mental illnesses are a leading cause of disability globally, and functional disability is often in part caused by cognitive impairments across psychiatric disorders. However, studies have consistently reported seemingly opposite findings regarding the association between cognition and psychiatric symptoms.</p><p><strong>Objective: </strong>To determine if the association between general cognition and mental health symptoms diverges at different symptom severities in children.</p><p><strong>Design, setting, and participants: </strong>A total of 5175 children with complete data at 2 time points assessed 2 years apart (aged 9 to 11 years at the first assessment) from the ongoing Adolescent Brain and Cognitive Development (ABCD) study were evaluated for a general cognition factor and mental health symptoms from September 2016 to August 2020 at 21 sites across the US. Polynomial and generalized additive models afforded derivation of continuous associations between cognition and psychiatric symptoms across different ranges of symptom severity. Data were analyzed from December 2022 to April 2024.</p><p><strong>Main outcomes and measures: </strong>Aggregate cognitive test scores (general cognition) were primarily evaluated in relation to total and subscale-specific symptoms reported from the Child Behavioral Checklist.</p><p><strong>Results: </strong>The sample included 5175 children (2713 male [52.4%] and 2462 female [47.6%]; mean [SD] age, 10.9 [1.18] years). Previously reported mixed findings regarding the association between general cognition and symptoms may consist of several underlying, opposed associations that depend on the class and severity of symptoms. Linear models recovered differing associations between general cognition and mental health symptoms, depending on the range of symptom severities queried. Nonlinear models confirm that internalizing symptoms were significantly positively associated with cognition at low symptom burdens higher cognition = more symptoms) and significantly negatively associated with cognition at high symptom burdens.</p><p><strong>Conclusions and relevance: </strong>The association between mental health symptoms and general cognition in this study was nonlinear. Internalizing symptoms were both positively and negatively associated with general cognition at a significant level, depending on the range of symptom severities queried in the analysis sample. These results appear to reconcile mixed findings in prior studies, which implicitly assume that symptom severity tracks linearly with cognitive ability across the entire spectrum of mental health. As the association between cognition and symptoms may be opposite in low vs high symptom severity samples, these results reveal the necessity of clinical enrichment in studies of cognitive impairment.</p>","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"1236-1245"},"PeriodicalIF":22.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11359114/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142080334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk of Suicide Across Medical Conditions and the Role of Prior Mental Disorder. 各种医疗状况下的自杀风险以及先前精神障碍的作用。
IF 22.5 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-12-01 DOI: 10.1001/jamapsychiatry.2024.2561
Søren Dinesen Østergaard, Natalie C Momen, Uffe Heide-Jørgensen, Oleguer Plana-Ripoll

Importance: According to the World Health Organization, more than 700 000 individuals worldwide die by suicide each year. Medical conditions likely increase the risk of suicide.

Objective: To (1) provide age- and sex-specific pairwise estimates of the risk of suicide across a comprehensive range of medical conditions, (2) investigate whether there is a dose-response-like relationship at play (ie, the higher the disability burden due to medical morbidity, the higher the risk of suicide), and (3) determine if the risk of suicide with medical conditions is particularly pronounced among those who had mental disorder preceding the medical conditions.

Design, setting, and participants: This cohort study was an observational study of population-based data for all individuals living in Denmark at some point between 2000 and 2020. The data analysis took place from September 2023 to May 2024.

Exposures: Thirty-one specific medical conditions as well as prior mental disorder.

Main outcomes and measures: The main outcome was suicide. Associations between the 31 specific medical conditions, nested within 9 categories, and suicide were examined via Poisson regression, yielding incidence rate ratios (IRRs). Subsequent analyses included an interaction term to assess whether a previous hospital-treated mental disorder modified the associations. Finally, the association between the disability burden of medical conditions and suicide was examined for those with and without prior mental disorder, respectively.

Results: A total of 6 635 857 individuals (3 337 613 females and 3 298 244 males) were included in the analyses of the associations between medical conditions and suicide. Except for endocrine disorders, all categories of medical conditions were associated with a statistically significant increased risk of suicide (which was most pronounced for gastrointestinal conditions [IRR, 1.7; 95% CI,1.5-1.8], cancer [IRR, 1.5; 95% CI, 1.4-1.6], and hematological conditions [IRR, 1.5; 95% CI, 1.3-1.6]). Interaction between mental disorder and individual medical conditions did not seem to play a major role for suicide risk. For those without but not for those with mental disorder, there was a dose-response-like relationship between the disability burden of medical conditions and suicide.

Conclusions and relevance: Medical conditions are generally associated with increased risk of suicide in a dose-response-like manner. Individuals with hospital-treated mental disorder appear to be at such elevated risk of suicide that additional disability associated with medical conditions has little impact in this regard.

重要性:据世界卫生组织统计,全世界每年有 70 多万人死于自杀。医疗条件可能会增加自杀风险:目的:(1) 对各种医疗状况下的自杀风险进行按年龄和性别配对的估算;(2) 研究是否存在剂量-反应关系(即医疗疾病导致的残疾负担越重,自杀风险越高);(3) 确定医疗状况导致的自杀风险是否在医疗状况之前患有精神障碍的人群中尤为明显:这项队列研究是一项基于人口数据的观察性研究,研究对象是 2000 年至 2020 年间居住在丹麦的所有人。数据分析时间为 2023 年 9 月至 2024 年 5 月:主要结果和测量指标:主要结果是自杀:主要结果是自杀。通过泊松回归检验了 31 种特定病症(嵌套在 9 个类别中)与自杀之间的关联,得出了发病率比 (IRR)。随后的分析中加入了交互项,以评估曾在医院接受过治疗的精神障碍是否会改变两者之间的关系。最后,我们还分别研究了曾患有和未患有精神障碍的患者的医疗条件残疾负担与自杀之间的关联:共有 6 635 857 人(女性 3 337 613 人,男性 3 298 244 人)参与了病情与自杀之间的关联分析。除内分泌失调外,所有类别的病症都与自杀风险的增加有显著的统计学关联(其中胃肠道疾病[IRR,1.7;95% CI,1.5-1.8]、癌症[IRR,1.5;95% CI,1.4-1.6]和血液病[IRR,1.5;95% CI,1.3-1.6]最为明显)。精神障碍与个体医疗条件之间的相互作用似乎并没有对自杀风险产生重大影响。对于没有精神障碍的人来说,医疗条件的残疾负担与自杀之间存在剂量-反应关系,而对于有精神障碍的人来说则没有这种关系:医疗状况通常与自杀风险的增加呈剂量反应关系。接受过医院治疗的精神障碍患者的自杀风险似乎很高,因此与医疗状况相关的额外残疾对其影响不大。
{"title":"Risk of Suicide Across Medical Conditions and the Role of Prior Mental Disorder.","authors":"Søren Dinesen Østergaard, Natalie C Momen, Uffe Heide-Jørgensen, Oleguer Plana-Ripoll","doi":"10.1001/jamapsychiatry.2024.2561","DOIUrl":"10.1001/jamapsychiatry.2024.2561","url":null,"abstract":"<p><strong>Importance: </strong>According to the World Health Organization, more than 700 000 individuals worldwide die by suicide each year. Medical conditions likely increase the risk of suicide.</p><p><strong>Objective: </strong>To (1) provide age- and sex-specific pairwise estimates of the risk of suicide across a comprehensive range of medical conditions, (2) investigate whether there is a dose-response-like relationship at play (ie, the higher the disability burden due to medical morbidity, the higher the risk of suicide), and (3) determine if the risk of suicide with medical conditions is particularly pronounced among those who had mental disorder preceding the medical conditions.</p><p><strong>Design, setting, and participants: </strong>This cohort study was an observational study of population-based data for all individuals living in Denmark at some point between 2000 and 2020. The data analysis took place from September 2023 to May 2024.</p><p><strong>Exposures: </strong>Thirty-one specific medical conditions as well as prior mental disorder.</p><p><strong>Main outcomes and measures: </strong>The main outcome was suicide. Associations between the 31 specific medical conditions, nested within 9 categories, and suicide were examined via Poisson regression, yielding incidence rate ratios (IRRs). Subsequent analyses included an interaction term to assess whether a previous hospital-treated mental disorder modified the associations. Finally, the association between the disability burden of medical conditions and suicide was examined for those with and without prior mental disorder, respectively.</p><p><strong>Results: </strong>A total of 6 635 857 individuals (3 337 613 females and 3 298 244 males) were included in the analyses of the associations between medical conditions and suicide. Except for endocrine disorders, all categories of medical conditions were associated with a statistically significant increased risk of suicide (which was most pronounced for gastrointestinal conditions [IRR, 1.7; 95% CI,1.5-1.8], cancer [IRR, 1.5; 95% CI, 1.4-1.6], and hematological conditions [IRR, 1.5; 95% CI, 1.3-1.6]). Interaction between mental disorder and individual medical conditions did not seem to play a major role for suicide risk. For those without but not for those with mental disorder, there was a dose-response-like relationship between the disability burden of medical conditions and suicide.</p><p><strong>Conclusions and relevance: </strong>Medical conditions are generally associated with increased risk of suicide in a dose-response-like manner. Individuals with hospital-treated mental disorder appear to be at such elevated risk of suicide that additional disability associated with medical conditions has little impact in this regard.</p>","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"1198-1206"},"PeriodicalIF":22.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11375527/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142125780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Error in Results and Figure. 结果和图表中的错误。
IF 22.5 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-12-01 DOI: 10.1001/jamapsychiatry.2024.4051
{"title":"Error in Results and Figure.","authors":"","doi":"10.1001/jamapsychiatry.2024.4051","DOIUrl":"10.1001/jamapsychiatry.2024.4051","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"1279"},"PeriodicalIF":22.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11579883/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
JAMA Psychiatry.
IF 22.5 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-12-01 DOI: 10.1001/jamapsychiatry.2023.3952
{"title":"JAMA Psychiatry.","authors":"","doi":"10.1001/jamapsychiatry.2023.3952","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2023.3952","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":"81 12","pages":"1164"},"PeriodicalIF":22.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Architecture for Transformation in Child Mental Health. 儿童精神健康转型架构。
IF 22.5 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-12-01 DOI: 10.1001/jamapsychiatry.2024.3072
John N Constantino, Laura J Dilly
{"title":"An Architecture for Transformation in Child Mental Health.","authors":"John N Constantino, Laura J Dilly","doi":"10.1001/jamapsychiatry.2024.3072","DOIUrl":"10.1001/jamapsychiatry.2024.3072","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"1165-1166"},"PeriodicalIF":22.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142390685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis. 经典迷幻药研究中的不良事件:系统回顾与元分析》。
IF 22.5 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-12-01 DOI: 10.1001/jamapsychiatry.2024.2546
Jared T Hinkle, Marianna Graziosi, Sandeep M Nayak, David B Yaden
<p><strong>Importance: </strong>A clear and comprehensive understanding of risks associated with psychedelic-assisted therapy is necessary as investigators extend its application to new populations and indications.</p><p><strong>Objective: </strong>To assess adverse events (AEs) associated with classic psychedelics, particularly serious AEs (SAEs) and nonserious AEs (NSAEs) requiring medical or psychiatric evaluation.</p><p><strong>Data sources: </strong>The search for potentially eligible studies was conducted in the Scopus, MEDLINE, PsycINFO, and Web of Science databases from inception through February 8, 2024.</p><p><strong>Study selection: </strong>Two independent reviewers screened articles of classic psychedelics (lysergic acid diethylamide [LSD], psilocybin, dimethyltryptamine [DMT], and 5-methoxy-N,N-dimethyltryptamine [5-MeO-DMT]) involving administration in clinical or research contexts.</p><p><strong>Data extraction and synthesis: </strong>AE data were extracted and synthesized by 2 reviewers and were used for random-effects meta-analysis of AE frequency and heterogeneity. Risk of bias assessment focused on AE ascertainment (eg, systematic assessment and quality of follow-up).</p><p><strong>Main outcomes and measures: </strong>A hybrid approach was used for capture of all reported AEs following high-dose classic psychedelic exposure and confirmatory capture of AEs of special interest, including suicidality, psychotic disorder, manic symptoms, cardiovascular events, and hallucinogen persisting perception disorder. AEs were stratified by timescale and study population type. Forest plots of common AEs were generated, and the proportions of participants affected by SAEs or NSAEs requiring medical intervention were summarized descriptively.</p><p><strong>Results: </strong>A total of 214 unique studies were included, of which 114 (53.3%) reported analyzable AE data for 3504 total participants. SAEs were reported for no healthy participants and for approximately 4% of participants with preexisting neuropsychiatric disorders; among these SAEs were worsening depression, suicidal behavior, psychosis, and convulsive episodes. NSAEs requiring medical intervention (eg, paranoia, headache) were similarly rare. In contemporary research settings, there were no reports of deaths by suicide, persistent psychotic disorders, or hallucinogen persisting perception disorders following administration of high-dose classic psychedelics. However, there was significant heterogeneity in the quality of AE monitoring and reporting. Of 68 analyzed studies published since 2005, only 16 (23.5%) described systematic approaches to AE assessment, and 20 studies (29.4%) reported all AEs, as opposed to only adverse drug reactions. Meta-analyses of prevalence for common AEs (eg, headache, anxiety, nausea, fatigue, and dizziness) yielded comparable results for psilocybin and LSD.</p><p><strong>Conclusions and relevance: </strong>In this systematic review and meta-analysis, cl
重要性:随着研究人员将迷幻辅助疗法应用于新的人群和适应症,有必要清楚而全面地了解与之相关的风险:评估与经典迷幻药相关的不良事件(AEs),尤其是需要进行医疗或精神评估的严重不良事件(SAEs)和非严重不良事件(NSAEs):从开始到 2024 年 2 月 8 日,在 Scopus、MEDLINE、PsycINFO 和 Web of Science 数据库中对可能符合条件的研究进行了检索:两名独立审稿人筛选了涉及临床或研究用药的经典迷幻药(麦角酰二乙胺[LSD]、迷幻药、二甲基色胺[DMT]和 5-甲氧基-N,N-二甲基色胺[5-MeO-DMT])的文章:AE数据由两名审稿人提取和综合,并用于AE频率和异质性的随机效应荟萃分析。偏倚风险评估侧重于AE的确定(如系统评估和随访质量):主要结果和测量方法:采用混合方法采集高剂量典型迷幻药暴露后报告的所有AE,并确认采集特别关注的AE,包括自杀、精神病性障碍、躁狂症状、心血管事件和致幻剂持续感知障碍。AEs按时间尺度和研究人群类型进行了分层。生成了常见AEs的森林图,并对受SAEs或NSAEs影响而需要医疗干预的参与者比例进行了描述性总结:结果:共纳入了 214 项独特的研究,其中 114 项(53.3%)报告了 3504 名参与者的可分析 AE 数据。没有健康参试者发生 SAE,约 4% 的参试者患有原有的神经精神疾病;这些 SAE 包括抑郁症恶化、自杀行为、精神病和惊厥发作。需要医疗干预的非甾体抗炎药物不良反应(如妄想症、头痛)同样罕见。在当代研究环境中,没有关于服用大剂量经典迷幻药后出现自杀死亡、持续性精神障碍或幻觉持续感知障碍的报告。然而,在AE监测和报告的质量方面存在着明显的异质性。在 2005 年以来发表的 68 项分析研究中,只有 16 项(23.5%)介绍了系统的 AE 评估方法,20 项研究(29.4%)报告了所有 AE,而非仅报告了药物不良反应。对常见 AEs(如头痛、焦虑、恶心、疲劳和头晕)发生率的元分析结果显示,迷幻药和迷幻剂的 AEs 发生率相当:在这项系统综述和荟萃分析中,根据现有文献,经典迷幻药在临床或研究环境中的耐受性一般都很好,但也有发生 SAE 的情况。这些结果提供了常见AE频率的估计值,并表明在娱乐或非临床环境中报告的某些灾难性事件尚未在当代试验参与者中报告。要了解这些物质的风险和益处,并将这些风险传达给未来的研究参与者和公众,就需要进行仔细、持续和改进的药物警戒。
{"title":"Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis.","authors":"Jared T Hinkle, Marianna Graziosi, Sandeep M Nayak, David B Yaden","doi":"10.1001/jamapsychiatry.2024.2546","DOIUrl":"10.1001/jamapsychiatry.2024.2546","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;A clear and comprehensive understanding of risks associated with psychedelic-assisted therapy is necessary as investigators extend its application to new populations and indications.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To assess adverse events (AEs) associated with classic psychedelics, particularly serious AEs (SAEs) and nonserious AEs (NSAEs) requiring medical or psychiatric evaluation.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Data sources: &lt;/strong&gt;The search for potentially eligible studies was conducted in the Scopus, MEDLINE, PsycINFO, and Web of Science databases from inception through February 8, 2024.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Study selection: &lt;/strong&gt;Two independent reviewers screened articles of classic psychedelics (lysergic acid diethylamide [LSD], psilocybin, dimethyltryptamine [DMT], and 5-methoxy-N,N-dimethyltryptamine [5-MeO-DMT]) involving administration in clinical or research contexts.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Data extraction and synthesis: &lt;/strong&gt;AE data were extracted and synthesized by 2 reviewers and were used for random-effects meta-analysis of AE frequency and heterogeneity. Risk of bias assessment focused on AE ascertainment (eg, systematic assessment and quality of follow-up).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;A hybrid approach was used for capture of all reported AEs following high-dose classic psychedelic exposure and confirmatory capture of AEs of special interest, including suicidality, psychotic disorder, manic symptoms, cardiovascular events, and hallucinogen persisting perception disorder. AEs were stratified by timescale and study population type. Forest plots of common AEs were generated, and the proportions of participants affected by SAEs or NSAEs requiring medical intervention were summarized descriptively.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 214 unique studies were included, of which 114 (53.3%) reported analyzable AE data for 3504 total participants. SAEs were reported for no healthy participants and for approximately 4% of participants with preexisting neuropsychiatric disorders; among these SAEs were worsening depression, suicidal behavior, psychosis, and convulsive episodes. NSAEs requiring medical intervention (eg, paranoia, headache) were similarly rare. In contemporary research settings, there were no reports of deaths by suicide, persistent psychotic disorders, or hallucinogen persisting perception disorders following administration of high-dose classic psychedelics. However, there was significant heterogeneity in the quality of AE monitoring and reporting. Of 68 analyzed studies published since 2005, only 16 (23.5%) described systematic approaches to AE assessment, and 20 studies (29.4%) reported all AEs, as opposed to only adverse drug reactions. Meta-analyses of prevalence for common AEs (eg, headache, anxiety, nausea, fatigue, and dizziness) yielded comparable results for psilocybin and LSD.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions and relevance: &lt;/strong&gt;In this systematic review and meta-analysis, cl","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"1225-1235"},"PeriodicalIF":22.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11375525/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142125760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Grief-Specific Cognitive Behavioral Therapy vs Present-Centered Therapy 悲伤认知行为疗法与以现在为中心的疗法
IF 25.8 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-11-13 DOI: 10.1001/jamapsychiatry.2024.3409
Rita Rosner, Jörn Rau, Anette Kersting, Winfried Rief, Regina Steil, Anna-Maria Rummel, Anna Vogel, Hannah Comtesse
ImportanceProlonged grief disorder (PGD) is included as a new diagnosis in international classification systems. Treatments following a cognitive behavioral model are most effective, but comparisons with active control treatments are scarce.ObjectiveTo examine whether integrative cognitive behavioral therapy for prolonged grief (PG-CBT) is superior to present-centered therapy (PCT).Design, Setting, and ParticipantsThis was a rater-blinded, multicenter, randomized clinical trial (stratified by center and relationship to the deceased) with enrollment from April 2017 to May 2022. The setting included 4 university outpatient clinics in Germany. Eligible participants were aged 18 to 75 years and had PGD based on the Prolonged Grief Disorder 13 (PG-13) interview. Participants were randomized 1:1 to PG-CBT and PCT.InterventionsPG-CBT focused on the exposure to the worst moment of the loss and cognitive restructuring of grief-related cognitions in combination with solution-focused and experiential methods (eg, walk to the grave exercise). PCT was adapted in session length and number to PG-CBT and focused on a supportive relationship and coping with daily problems that may have arisen from the loss or grief symptoms.Main Outcomes and MeasuresAll outcomes were assessed at baseline, after treatment, and 12 months after randomization at follow-up. The primary outcome was a blinded assessment of the PG-13 severity score at follow-up. Secondary outcomes were self-reported depressive, somatic, and overall psychopathological symptoms.ResultsOf 544 treatment-seeking individuals experiencing bereavement, 212 eligible participants (mean [SD] age, 51.8 [13.3] years; 173 female [82%]) with PGD based on the PG-13 interview were randomized to PG-CBT and PCT (n = 106 in each condition). In the intention-to-treat analysis, both treatments yielded high reductions in PGD severity at follow-up (PG-CBT: Cohen <jats:italic>d</jats:italic> = 1.64; 95% CI, 1.31-1.97; PCT: Cohen <jats:italic>d</jats:italic> = 1.38; 95% CI, 1.09-1.66). After treatment, participants receiving PG-CBT demonstrated significantly greater reductions in PGD severity than those receiving PCT (Cohen <jats:italic>d</jats:italic> = 0.31; 95% CI, 0.03-0.57). At follow-up, this effect was only visible on a trend level (Cohen <jats:italic>d</jats:italic> = 0.28; 95% CI, −0.02 to 0.57), whereas participants in the PG-CBT group had significantly less depressive and general psychopathological symptoms. Twenty-three participants (20%) discontinued PG-CBT treatment, and 17 participants (16%) discontinued PCT.Conclusion and RelevanceThis randomized clinical trial demonstrates that PG-CBT was superior to PCT after treatment and at follow-up with regard to comorbid symptoms. Both treatments were shown to be effective and acceptable, showing the potential for dissemination and increasing patient choice.Trial registrationGerman Clinical Trials Register (DRKS) identifier: <jats:ext-link xmlns:xlink="http://www.w3.org/199
重要性长期悲伤障碍(PGD)作为一种新的诊断被纳入国际分类系统。采用认知行为模式的治疗最为有效,但与积极对照治疗的比较却很少。目的研究针对长期悲伤的整合认知行为疗法(PG-CBT)是否优于以现在为中心的疗法(PCT)。设计、环境和参与者这是一项评分者盲法、多中心、随机临床试验(根据中心和与逝者的关系进行分层),入组时间为2017年4月至2022年5月。试验地点包括德国的 4 所大学门诊部。符合条件的参与者年龄在18至75岁之间,并根据 "长期悲伤障碍13"(PG-13)访谈结果患有PGD。干预PG-CBT的重点是让患者面对失去亲人的最糟糕时刻,并结合以解决问题为中心的方法和体验式方法(如步行到坟墓锻炼)对悲伤相关认知进行认知重组。PCT在疗程长度和次数上与PG-CBT相适应,并侧重于支持性关系和应对可能由丧失或悲伤症状引起的日常问题。主要结果和测量所有结果均在基线、治疗后和随机化后12个月的随访中进行评估。主要结果是对随访时的 PG-13 严重程度进行盲法评估。结果在 544 名寻求治疗的丧亲人士中,有 212 名符合条件的参与者(平均 [SD] 年龄 51.8 [13.3] 岁;173 名女性 [82%])根据 PG-13 访谈结果患有 PGD,他们被随机分配到 PG-CBT 和 PCT 治疗中(每种治疗方法的人数均为 106 人)。在意向治疗分析中,两种治疗方法都能在随访时显著降低 PGD 的严重程度(PG-CBT:Cohen d = 1.64;95% CI,1.31-1.97;PCT:Cohen d = 1.38;95% CI,1.09-1.66)。治疗后,接受 PG-CBT 的参与者的 PGD 严重程度明显低于接受 PCT 的参与者(Cohen d = 0.31;95% CI,0.03-0.57)。在随访中,这一效果仅在趋势水平上可见(Cohen d = 0.28;95% CI,-0.02 至 0.57),而 PG-CBT 组参与者的抑郁症状和一般精神病理症状明显减少。23名参与者(20%)中断了PG-CBT治疗,17名参与者(16%)中断了PCT治疗。结论与相关性这项随机临床试验表明,在治疗后和随访期间,就合并症状而言,PG-CBT优于PCT。两种治疗方法均有效且可接受,显示了推广和增加患者选择的潜力:DRKS00012317
{"title":"Grief-Specific Cognitive Behavioral Therapy vs Present-Centered Therapy","authors":"Rita Rosner, Jörn Rau, Anette Kersting, Winfried Rief, Regina Steil, Anna-Maria Rummel, Anna Vogel, Hannah Comtesse","doi":"10.1001/jamapsychiatry.2024.3409","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2024.3409","url":null,"abstract":"ImportanceProlonged grief disorder (PGD) is included as a new diagnosis in international classification systems. Treatments following a cognitive behavioral model are most effective, but comparisons with active control treatments are scarce.ObjectiveTo examine whether integrative cognitive behavioral therapy for prolonged grief (PG-CBT) is superior to present-centered therapy (PCT).Design, Setting, and ParticipantsThis was a rater-blinded, multicenter, randomized clinical trial (stratified by center and relationship to the deceased) with enrollment from April 2017 to May 2022. The setting included 4 university outpatient clinics in Germany. Eligible participants were aged 18 to 75 years and had PGD based on the Prolonged Grief Disorder 13 (PG-13) interview. Participants were randomized 1:1 to PG-CBT and PCT.InterventionsPG-CBT focused on the exposure to the worst moment of the loss and cognitive restructuring of grief-related cognitions in combination with solution-focused and experiential methods (eg, walk to the grave exercise). PCT was adapted in session length and number to PG-CBT and focused on a supportive relationship and coping with daily problems that may have arisen from the loss or grief symptoms.Main Outcomes and MeasuresAll outcomes were assessed at baseline, after treatment, and 12 months after randomization at follow-up. The primary outcome was a blinded assessment of the PG-13 severity score at follow-up. Secondary outcomes were self-reported depressive, somatic, and overall psychopathological symptoms.ResultsOf 544 treatment-seeking individuals experiencing bereavement, 212 eligible participants (mean [SD] age, 51.8 [13.3] years; 173 female [82%]) with PGD based on the PG-13 interview were randomized to PG-CBT and PCT (n = 106 in each condition). In the intention-to-treat analysis, both treatments yielded high reductions in PGD severity at follow-up (PG-CBT: Cohen &lt;jats:italic&gt;d&lt;/jats:italic&gt; = 1.64; 95% CI, 1.31-1.97; PCT: Cohen &lt;jats:italic&gt;d&lt;/jats:italic&gt; = 1.38; 95% CI, 1.09-1.66). After treatment, participants receiving PG-CBT demonstrated significantly greater reductions in PGD severity than those receiving PCT (Cohen &lt;jats:italic&gt;d&lt;/jats:italic&gt; = 0.31; 95% CI, 0.03-0.57). At follow-up, this effect was only visible on a trend level (Cohen &lt;jats:italic&gt;d&lt;/jats:italic&gt; = 0.28; 95% CI, −0.02 to 0.57), whereas participants in the PG-CBT group had significantly less depressive and general psychopathological symptoms. Twenty-three participants (20%) discontinued PG-CBT treatment, and 17 participants (16%) discontinued PCT.Conclusion and RelevanceThis randomized clinical trial demonstrates that PG-CBT was superior to PCT after treatment and at follow-up with regard to comorbid symptoms. Both treatments were shown to be effective and acceptable, showing the potential for dissemination and increasing patient choice.Trial registrationGerman Clinical Trials Register (DRKS) identifier: &lt;jats:ext-link xmlns:xlink=\"http://www.w3.org/199","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":"22 1","pages":""},"PeriodicalIF":25.8,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142610551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emergency Department Visits Involving Hallucinogen Use and Risk of Schizophrenia Spectrum Disorder 使用致幻剂的急诊就诊与精神分裂症谱系障碍的风险
IF 25.8 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-11-13 DOI: 10.1001/jamapsychiatry.2024.3532
Daniel T. Myran, Michael Pugliese, Jennifer Xiao, Tyler S. Kaster, M. Ishrat Husain, Kelly K. Anderson, Nicholas Fabiano, Stanley Wong, Jess G. Fiedorowicz, Colleen Webber, Peter Tanuseputro, Marco Solmi
ImportanceInterest in and use of hallucinogens has been increasing rapidly. While a frequently raised concern is that hallucinogens may be associated with an increased risk of psychosis, there are limited data on this association.ObjectivesTo examine whether individuals with an emergency department (ED) visit involving hallucinogen use have an increased risk of developing a schizophrenia spectrum disorder (SSD).Design, Settings, and ParticipantsThis population-based, retrospective cohort study (January 2008 to December 2021) included all individuals aged 14 to 65 years in Ontario, Canada, with no history of psychosis (SSD or substance induced). Data were analyzed from May to August 2024.ExposureAn incident ED visit involving hallucinogen use.Main Outcomes and MeasuresDiagnosis of SSD using a medical record–validated algorithm. Associations between ED visits involving hallucinogens and SSD were estimated using cause-specific adjusted hazard models. Individuals with an incident ED visit involving hallucinogens were compared with members of the general population (primary analysis) or individuals with ED visits involving alcohol or cannabis (secondary analysis).ResultsThe study included 9 244 292 individuals (mean [SD] age, 40.4 [14.7] years; 50.2% female) without a history of psychosis, with a median follow-up of 5.1 years (IQR, 2.3-8.6 years); 5217 (0.1%) had an incident ED visit involving hallucinogen use. Annual rates of incident ED visits involving hallucinogens were stable between 2008 and 2012 and then increased by 86.4% between 2013 and 2021 (3.4 vs 6.4 per 100 000 individuals). Individuals with ED visits involving hallucinogens had a greater risk of being diagnosed with an SSD within 3 years compared with the general population (age- and sex-adjusted hazard ratio [HR], 21.32 [95% CI, 18.58-24.47]; absolute proportion with SSD at 3 years, 208 of 5217 with hallucinogen use [3.99%] vs 13 639 of 9 239 075 in the general population [0.15%]). After adjustment for comorbid substance use and mental health conditions, individuals with hallucinogen ED visits had a greater risk of SSD compared with the general population (HR, 3.53; 95% CI, 3.05-4.09). Emergency department visits involving hallucinogens were associated with an increased risk of SSD within 3 years compared with ED visits involving alcohol (HR, 4.66; 95% CI, 3.82-5.68) and cannabis (HR, 1.47; 95% CI, 1.21-1.80) in the fully adjusted model.Conclusions and RelevanceIn this cohort study, individuals with an ED visit involving hallucinogen use had a greater risk of developing an SSD compared with both the general population and with individuals with ED visits for other types of substances. These findings have important clinical and policy implications given the increasing use of hallucinogens and associated ED visits.
重要性人们对致幻剂的兴趣和使用在迅速增加。这项基于人群的回顾性队列研究(2008 年 1 月至 2021 年 12 月)纳入了加拿大安大略省所有年龄在 14 岁至 65 岁之间、无精神病史(SSD 或药物诱发)的人。主要结果和测量指标使用经过医疗记录验证的算法诊断出 SSD。使用病因特异性调整危险模型估算涉及致幻剂的急诊就诊与 SSD 之间的关系。研究纳入了 9 244 292 人(平均 [SD] 年龄为 40.4 [14.7] 岁;50.2% 为女性),均无精神病史,中位随访时间为 5.1 年(IQR,2.3-8.6 年);5217 人(0.1%)曾因使用致幻剂而在急诊就诊。2008年至2012年期间,使用致幻剂的急诊室就诊率保持稳定,2013年至2021年期间增加了86.4%(每10万人中有3.4人就诊,每10万人中有6.4人就诊)。与普通人群相比,使用致幻剂的 ED 患者在 3 年内被诊断为 SSD 的风险更高(经年龄和性别调整后的危险比 [HR],21.32 [95% CI,18.58-24.47];3 年后患 SSD 的绝对比例为:使用致幻剂的 5217 人中有 208 人 [3.99%] ,而普通人群为 9 239 075 人中有 13 639 人 [0.15%])。在对合并药物使用和精神健康状况进行调整后,与普通人群相比,使用致幻剂的急诊就诊者患 SSD 的风险更高(HR,3.53;95% CI,3.05-4.09)。在完全调整模型中,与使用酒精(HR,4.66;95% CI,3.82-5.68)和大麻(HR,1.47;95% CI,1.21-1.80)的急诊就诊相比,使用致幻剂的急诊就诊者在 3 年内罹患 SSD 的风险更高。在这项队列研究中,与普通人群和使用其他类型药物的急诊就诊者相比,使用致幻剂的急诊就诊者罹患 SSD 的风险更高。鉴于致幻剂的使用和相关的急诊就诊日益增多,这些发现对临床和政策具有重要意义。
{"title":"Emergency Department Visits Involving Hallucinogen Use and Risk of Schizophrenia Spectrum Disorder","authors":"Daniel T. Myran, Michael Pugliese, Jennifer Xiao, Tyler S. Kaster, M. Ishrat Husain, Kelly K. Anderson, Nicholas Fabiano, Stanley Wong, Jess G. Fiedorowicz, Colleen Webber, Peter Tanuseputro, Marco Solmi","doi":"10.1001/jamapsychiatry.2024.3532","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2024.3532","url":null,"abstract":"ImportanceInterest in and use of hallucinogens has been increasing rapidly. While a frequently raised concern is that hallucinogens may be associated with an increased risk of psychosis, there are limited data on this association.ObjectivesTo examine whether individuals with an emergency department (ED) visit involving hallucinogen use have an increased risk of developing a schizophrenia spectrum disorder (SSD).Design, Settings, and ParticipantsThis population-based, retrospective cohort study (January 2008 to December 2021) included all individuals aged 14 to 65 years in Ontario, Canada, with no history of psychosis (SSD or substance induced). Data were analyzed from May to August 2024.ExposureAn incident ED visit involving hallucinogen use.Main Outcomes and MeasuresDiagnosis of SSD using a medical record–validated algorithm. Associations between ED visits involving hallucinogens and SSD were estimated using cause-specific adjusted hazard models. Individuals with an incident ED visit involving hallucinogens were compared with members of the general population (primary analysis) or individuals with ED visits involving alcohol or cannabis (secondary analysis).ResultsThe study included 9 244 292 individuals (mean [SD] age, 40.4 [14.7] years; 50.2% female) without a history of psychosis, with a median follow-up of 5.1 years (IQR, 2.3-8.6 years); 5217 (0.1%) had an incident ED visit involving hallucinogen use. Annual rates of incident ED visits involving hallucinogens were stable between 2008 and 2012 and then increased by 86.4% between 2013 and 2021 (3.4 vs 6.4 per 100 000 individuals). Individuals with ED visits involving hallucinogens had a greater risk of being diagnosed with an SSD within 3 years compared with the general population (age- and sex-adjusted hazard ratio [HR], 21.32 [95% CI, 18.58-24.47]; absolute proportion with SSD at 3 years, 208 of 5217 with hallucinogen use [3.99%] vs 13 639 of 9 239 075 in the general population [0.15%]). After adjustment for comorbid substance use and mental health conditions, individuals with hallucinogen ED visits had a greater risk of SSD compared with the general population (HR, 3.53; 95% CI, 3.05-4.09). Emergency department visits involving hallucinogens were associated with an increased risk of SSD within 3 years compared with ED visits involving alcohol (HR, 4.66; 95% CI, 3.82-5.68) and cannabis (HR, 1.47; 95% CI, 1.21-1.80) in the fully adjusted model.Conclusions and RelevanceIn this cohort study, individuals with an ED visit involving hallucinogen use had a greater risk of developing an SSD compared with both the general population and with individuals with ED visits for other types of substances. These findings have important clinical and policy implications given the increasing use of hallucinogens and associated ED visits.","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":"70 1","pages":""},"PeriodicalIF":25.8,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142610548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
JAMA Psychiatry
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1